Praxis Precision Medicines, Inc. (PRAX) Stock Price & Analysis
Praxis Precision Medicines, Inc. (PRAX) closed at USD 258.92 on Thursday, October 22, 2026, up 0.96% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 256.47; the Oct 22, 2026 session ranged USD 253.05–263.5 on volume of 355,672 shares. Market capitalization is $7.23B, with a 52-week range of USD 154.45–392.7 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:12 UTC.
Also available as compact Markdown for AI agents: nexqual.com/PRAX.md
Key facts (PRAX)
- 1 of 80 tracked superinvestors hold PRAX (13F, Q2 2026): 0 new, 0 added, 1 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $3.6M; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.95 on a 1–5 scale) (21 analysts), mean target USD 650 (range 188–1,201).
- Total return with dividends: 1Y +45.5% vs S&P 500 +14.9%; 5Y -21.3% vs S&P 500 +80.3%.
- Next earnings: 2026-11-09, EPS estimate USD -3.63, revenue estimate $0K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (PRAX)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | — | $0K | $2.4M | $8.6M | $0K | — |
| Operating income | -$167M | -$215M | -$126M | -$200M | -$326M | -$378M |
| Net income | -$167M | -$214M | -$123M | -$183M | -$303M | -$339M |
| EPS (diluted) | -$59.10 | -$69.65 | -$18.69 | -$10.21 | -$13.48 | — |
| Free cash flow | -$126M | -$185M | -$111M | -$132M | -$249M | -$305M |
| Operating margin | — | — | -5164.4% | -2340.3% | — | — |
| Net margin | — | — | -5037.9% | -2137.5% | — | — |
| Revenue growth | — | — | — | +249.5% | -100.0% | — |
| Cash + short-term investments | $276M | $100M | $0K | $470M | $926M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (PRAX)
P/B 5.4x · FCF yield -4.22% · Earnings yield -4.69%
Superinvestors (SEC 13F-HR, Q2 2026) (PRAX)
1 of 80 tracked investors hold PRAX. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Polen Capital | Polen Capital Management | 0.02% | $2.4M | Reduced -27.8% |
Insider sales (SEC Form 4, open-market, last ~7 months) (PRAX)
1 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-06-24 | Desimone Jill | Director | 11,600 | $3.6M | 83.2% | Yes (adopted March 25, 2026) | Too little history (no open-market trades in 2024 or 2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (PRAX)
Consensus Buy (mean 1.95 on a 1–5 scale), 21 analysts; mean target USD 650 (low 188, high 1,201).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-16 | JP Morgan | Initiated | Overweight | $700 |
| 2026-10-15 | UBS | Initiated | Buy | $706 |
| 2026-10-15 | HC Wainwright & Co. | Reiterated | Buy | $1201 |
| 2026-10-06 | HC Wainwright & Co. | Reiterated | Buy | $1201 |
| 2026-10-06 | BTIG | Target raised | Buy | $810 → $826 |
| 2026-09-24 | HC Wainwright & Co. | Reiterated | Buy | $1201 |
| 2026-09-24 | Needham | Reiterated | Buy | $582 |
| 2026-08-21 | Goldman Sachs | Target raised | Buy | $470 → $575 |
| 2026-08-07 | RBC Capital | Target raised | Outperform | $449 → $462 |
| 2026-08-07 | Wells Fargo | Target raised | Equal-Weight | $323 → $362 |
| 2026-08-06 | Needham | Target raised | Buy | $575 → $582 |
| 2026-07-29 | BTIG | Reiterated | Buy | $810 |
Total return (dividends reinvested) (PRAX)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +45.5% | -21.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +45.6% | -4.7% |
| Volatility (annualized) | 72.2% | 135.2% |
| Max drawdown | -38.1% (Aug 2026→Oct 2026) | -96.3% (Nov 2021→Mar 2023) |
PRAX suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | IONIS PHARMACEUTICALS INC (IONS) | “RogCon had an existing collaboration arrangement with Ionis Pharmaceuticals, Inc., or Ionis, and as a result, we and Ionis negotiated a Research Collaboration, Option and License Agreement, or the Ionis Agreement, (described below) in order to complete the license agreement with RogCon.” |
| Partner | RogCon | “In September 2019, we and RogCon, Inc., or RogCon, entered into a Cooperation and License Agreement, or the RogCon Agreement, to collaborate to develop ASOs for the treatment of epilepsy caused by mutations of the SCN2A gene.” |
Quoted from the company's 10-K filed Feb 19, 2026.
PRAX company outlook (results filed Aug 6, 2026)
- “Ulixacaltamide is the first and only investigational therapy to demonstrate positive results in a Phase 3 program in ET and was granted Breakthrough Therapy Designation by the FDA in December 2025. • NDA review is progressing as expected, with a PDUFA date of January 29, 2027. • The mid-cycle meeting was successfully completed and the FDA identified no major safety or efficacy concerns to date.”
- “The inspection was completed successfully, and no form 483 was issued. • Acknowledging the late-stage discussions with the FDA in relation to both applications, Praxis does not intend to communicate regulatory updates going forward until the expected PDUFA dates.”
- “The Company's cash, cash equivalents and marketable securities as of June 30, 2026 are expected to fund operations into 2028.”
Quoted word-for-word from the SEC 8-K results press release.
PRAX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-3.63 | $-4.03 | -9.7% | $0 | 19 |
| Next quarter (ends Dec 2026) | $-4.24 | $-4.34 | -2.1% | $830,710 | 19 |
| Current fiscal year (ends Dec 2026) | $-14.02 | $-15.32 | -8.5% | $830,710 | 19 |
| Next fiscal year (ends Dec 2027) | $-9.50 | $-9.66 | -1.6% | $345.1M | 18 |
PRAX options: expected move
Options price a move of about ±22.0% (±$56.90) by Nov 20, 2026, which includes earnings on Nov 9, 2026. Over the last 8 reports the stock moved ±10.7% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 97.7% | ±22.0% |
| Dec 18, 2026 | 56 | 93.2% | ±29.3% |
| Jan 15, 2027 | 84 | 87.8% | ±33.6% |
| Feb 19, 2027 | 119 | 94.6% | ±42.8% |
| May 21, 2027 | 210 | 83.0% | ±49.3% |
| Jun 17, 2027 | 237 | 80.9% | ±50.9% |
30-day implied volatility 89.9% vs 47.4% realized over the last 30 trading days. Put/call ratio (volume) 29.73. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:12 UTC)
| Price | USD 258.92 |
|---|---|
| Change | ▲ 0.96% (up) |
| Previous Close | USD 256.47 |
| Open | USD 253.05 |
| Day Range | USD 253.05 – 263.5 |
| 52-Week Range | USD 154.45 – 392.7 |
| Volume | 355,672 shares |
| Market Cap | $7.23B |
| Exchange | NMS |
Technical Analysis (PRAX)
Nexqual's technical model rates PRAX "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 09:12 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 36.81 (neutral) |
| vs SMA50 | Below (USD 312.97) |
| MACD | -15.59 (negative) |
Analyst Ratings (PRAX)
Wall Street analysts rate PRAX "Buy" based on 21 analysts, with a mean price target of USD 650 (range USD 188–1,201), per Nexqual as of October 23, 2026 at 09:12 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 21 |
| Mean Target | USD 650 |
| High Target | USD 1,201 |
| Low Target | USD 188 |
| Buy / Hold / Sell | 19 / 1 / 1 |
Earnings (PRAX)
| Next Earnings Date | 2026-11-09 |
|---|---|
| EPS Estimate | USD -3.63 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -2.87 vs est -3.69 ▲ beat |
| 2026-03-31 | USD -3.2 vs est -3.68 ▲ beat |
| 2025-12-31 | USD -3.5 vs est -3.13 ▼ miss |
| 2025-09-30 | USD -3.36 vs est -3.49 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:12 UTC.
Financials & Fundamentals (PRAX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -38.86% |
| Debt / Equity | 0 |
| Current Ratio | 15.73 |
| Total Cash | $758.55M |
| Total Debt | $1.09M |
Source: Nexqual, October 23, 2026 at 09:12 UTC.
Financial Health Score (PRAX)
Nexqual rates Praxis Precision Medicines, Inc.'s overall financial health "Weak" across five dimensions, as of October 23, 2026 at 09:12 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $759M cash vs $1M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$249M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -39%, ROA -25.7% |
Ownership (PRAX)
| Insider Ownership | +0.28% |
|---|---|
| Institutional Ownership | +123.46% |
| Shares Outstanding | 27.92M |
| Float | 24.08M |
| Short % of Float | +15.04% |
Source: Nexqual, October 23, 2026 at 09:12 UTC.
Leadership (PRAX)
Praxis Precision Medicines, Inc. is led by Marcio Silva De'Souza, President, CEO & Director, per Nexqual as of October 23, 2026 at 09:12 UTC.
| President, CEO & Director | Marcio Silva De'Souza |
|---|---|
| CFO & Treasurer | Timothy Edwin Kelly |
| Co-Founder and President of Research & Development | Steven Petrou B.Sc. (Hons.) |
| Chief Operating Officer | Megan T. Sniecinski |
Major Backers & Investors (PRAX)
Notable institutional backers of Praxis Precision Medicines, Inc. include Jupiter Topco LLC, FMR, LLC, Perceptive Advisors Llc, according to Nexqual as of October 23, 2026 at 09:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Jupiter Topco LLC | 12.25% |
| FMR, LLC | 8.3% |
| Perceptive Advisors Llc | 7.29% |
| Baker Bros. Advisors, LP | 6.28% |
| Orbis Allan Gray Ltd | 5.48% |
| Adage Capital Partners GP L.L.C. | 3.64% |
| JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | 2.64% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 9.2% |
| BlackRock | 8.21% |
| State Street | 3.68% |
Source: Nexqual, October 23, 2026 at 09:12 UTC.
From Praxis Precision Medicines, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- We submitted a New Drug Application, or NDA, for ulixacaltamide for the treatment of ET to the FDA, and have commenced commercial preparations and pre-launch activities.
- We may also rely on trademarks, copyrights and trade secrets relating to our proprietary technology platform and on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of neuroscience that may be important for the development of our business.
- Solidus™ is enabled by our proprietary, computational workflow to discover ASOs with desired drug-like properties to optimize for up/down-regulation, avoidance of toxic motifs and optimization of binding affinity and specificity.
- We strive to protect and enhance the proprietary technology, inventions and improvements that are commercially important to the development of our business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties.
Partnerships
- RogCon had an existing collaboration arrangement with Ionis Pharmaceuticals, Inc., or Ionis, and as a result, we and Ionis negotiated a Research Collaboration, Option and License Agreement, or the Ionis Agreement, (described below) in order to complete the license agreement with RogCon.
- Under the RogCon Agreement, we will conduct, at our own cost and expense, the research and development activities assigned to us under the research plan set out in the Research Collaboration, Option and License Agreement with Ionis.
Legal & Regulatory Risks (Item 1A, quoted)
- Our product candidates may be regulated as controlled substances, the making, use, sale, importation, exportation, and distribution of which are subject to significant regulation by the U.S. Drug Enforcement Administration, or DEA, and other regulatory agencies.
- Our product candidates may be classified as controlled substances, which are subject to state, federal, and foreign laws and regulations regarding their manufacture, use, sale, importation, exportation, and distribution. Among other things, controlled substances are regulated under the federal Controlled Substances Act of 1970, and regulations of the DEA.
- We could be subject to product liability lawsuits based on the use of our product candidates in clinical testing or, if obtained, following our products' marketing approval and commercialization.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
| TGTX | TG Therapeutics, Inc. | USD 53.16 | ▼ 0.08% |
| ARWR | Arrowhead Pharmaceuticals, Inc. | USD 58.36 | ▼ 0.82% |
| AXSM | Axsome Therapeutics, Inc. | USD 156.07 | ▼ 0.15% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:12 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt